Adial Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 8731 https://www.adialpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Dec 1st, 2022 2:55 pm
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 14th, 2022 1:30 pm
Forget Bargain Hunting: Play 5 Stocks With Rising P/E - Oct 19th, 2022 8:57 pm
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate - Sep 26th, 2022 4:43 pm
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain - Sep 26th, 2022 1:00 pm
Adial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate - Sep 6th, 2022 2:02 pm
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis - Sep 6th, 2022 1:00 pm
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher - Sep 1st, 2022 1:55 pm
Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises - Aug 29th, 2022 11:19 am
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer - Aug 22nd, 2022 8:30 pm
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results - Aug 16th, 2022 1:15 pm
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder - Jul 20th, 2022 11:00 am
EXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients - Jul 20th, 2022 10:45 am
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder - Jul 18th, 2022 1:25 pm
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley - Jun 28th, 2022 3:49 pm
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial - Jun 27th, 2022 1:16 pm
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence - Jun 14th, 2022 2:48 pm
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH - May 19th, 2022 1:25 pm
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results - May 16th, 2022 1:25 pm
Maravai LifeSciences Reports First Quarter 2022 Financial Results - May 5th, 2022 8:05 pm